Nasdaq Inc vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Nasdaq Inc trades at $93.58 (market cap $51.63B), while Nuvation Bio Inc. Class A Common Stock trades at $4.98 (market cap $1.74B). The key difference: Nasdaq Inc is far larger — about 29.7× Nuvation Bio Inc. Class A Common Stock's market cap, and Nasdaq Inc pays a 1.26% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 125 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| NDAQ | NUVB | |
|---|---|---|
Market Cap | $51.63B | $1.74B |
Volume | 2,668,175 | 9,289,619 |
Sector | Financials | Health |
52-Week High | $100.98 | $9.54 |
52-Week Low | $76.85 | $3.41 |
Typical Hold Time | 125 Days | 0 Days |
Enterprise Value | $58.09B | $1.33B |
Dividend Yield | 1.26% | — |
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $91.93, down 0.37% on the day, with strong fundamentals including 2025 revenue of $8.26B and net income of $1.79B. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.02 EPS. Technical indicators show a bearish overall signal despite bullish moving averages, with key support at $90 and resistance at $92-94.
NDAQ presents a compelling investment case with 61% analyst buy ratings and a $110.43 consensus price target, representing 20% upside. Strong profitability metrics (22.5% net margin, 16.5% ROE) and growing Financial Technology business offset technical weakness. Risks include market volatility exposure and competitive pressures in exchange services.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →